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 1 
Public and pharmacist perceptions regarding counterfeit medicine in Lebanon using focus groups 1 
 2 
Introduction 3 
 4 
Counterfeiting is a substantial problem that is growing worldwide and affects both developed and less 5 
developed countries (Alfadl et al. 2013). Counterfeit products are illegal, low priced and often of lower quality 6 
than their originals (Lai and Zaichkowsky 1999). When it is medicines being counterfeited, this is not only 7 
damaging to the pharmaceutical industries but also constitutes a significant threat to public health (Bird 2007). 8 
Counterfeiting in general represents around 5–7% of world trade, and around 10-30% of the global medicine 9 
supply chain could be counterfeit (UNODC 2006). 10 
 The incidence of counterfeit medicine (CFM) varies based on each country’s regulatory and enforcement 11 
system. Poor and developing countries with weak regulatory and enforcement systems have higher percentages 12 
of CFM (Chauvé 2008; Alfadl et al. 2013; Rajapandian et al. 2013). Developed countries are less vulnerable 13 
to CFM and are considered properly regulated with well-controlled systems, yet several cases have been 14 
discovered within their legal pharmaceutical distribution chains (Besançon 2008). 15 
 The most common factors that encourage counterfeiters to produce CFM are: lack of legislation 16 
prohibiting counterfeiting of medicine; weak or minimum enforcement of laws and disciplinary actions; the 17 
high cost of branded medicine; and a shortage of medicine supplies (Chauvé 2008; Alfadl et al. 2013; 18 
Rajapandian et al. 2013; Al-Worafi 2014). 19 
 CFMs play a major role in destroying the public’s trust in the healthcare team (Newton et al. 2006; Akiny 20 
2013) the safety and efficacy of pharmaceutical products (Newton et al. 2006); government and regulatory 21 
authorities in controlling the availability of CFM (Akiny 2013; Mdege et al. 2016). Moreover, ignorance of 22 
the risks and attributes of CFMs increases the vulnerability towards CFM use, causing lower detection and 23 
reporting rates for counterfeits (Akiny 2013). 24 
 The problem of CFM continues and the crisis of medicine shortages is still present, however, currently the 25 
economic, political, governmental and regulatory situations of each country, add to the reasons why CFMs are 26 
more readily available in some countries more than others (Chauvé 2008; Alfadl et al. 2013). For example, in 27 
Lebanon, a related study (Sholy 2015) explored the availability of CFM in various households in Lebanon and 28 
found the extent of CFM to range from 3% in Mount Lebanon (ML) to 12% in the Bekaa and South of Lebanon. 29 
 This study is part of a bigger research programme based on mixed-methods methodology (Hadi and Closs 30 
2016) that included points of interaction between the qualitative (sub-study) and quantitative (bigger study) 31 
components, using the explanatory sequential design. The data in this design are gathered sequentially in two 32 
phases. Phase one (the bigger study) used quantitative research that collected and analysed data from 33 
 2 
questionnaires (Sholy 2015; Sholy et al. 2017). Phase two is this study (sub-study) used qualitative research 34 
(focus groups) to explain the findings of the questionnaires in phase one (Hadi and Closs 2016). 35 
Focus groups (FG) and interviews are both useful qualitative methods (Rabiee 2004; Stewart and 36 
Shamdasani 2014). FG allow participants to listen to the opinion of others, gather views of several people 37 
simultaneously and understand the issues that would not be possible to generate without the interaction 38 
produced from group discussions (Krueger and Casey 2009). FG were used for convenience since they yield a 39 
large amount of data in a short period of time, while the one to one interviews would require more time (Rabiee 40 
2004; Stewart and Shamdasani 2014). 41 
There have been limited studies that used FG to explore perceptions about CFM with the public/ 42 
pharmacists (Syhakhang et al. 2004). A study in Sudan determined the factors related to CFM purchases using 43 
interviews (Alfadl et al. 2013), and another in Lao People’s Democratic Republic (PDR) (Syhakhang et al. 44 
2004) explored the knowledge and perceptions of medicine quality using interviews and FG. Both concluded 45 
that lack of knowledge, high prices and unaffordability of medicines have a major role in increasing the 46 
likelihood of the public using counterfeit or low quality medicine.  47 
 The findings of a related study (Sholy et al, 2017) suggested exploring the experiences, views and 48 
beliefs of the pharmacists/Public regarding CFM in Lebanon and how they can be limited/controlled. 49 
 50 
Aim of the study 51 
 52 
To explore the experiences, views and beliefs of the public and pharmacists regarding CFM. 53 
  54 
 3 
Method  55 
 56 
This study is descriptive and is based on phase two of a mixed-methods methodology, using the explanatory 57 
sequential design. The study used FG as the qualitative method to explore the general public and pharmacists’ 58 
experiences, views and beliefs towards CFM. Phase one of the study used questionnaires that assessed 849 59 
members of the public (Sholy 2015) and 223 practicing pharmacists on awareness and views towards CFM 60 
(Sholy et al. 2017). The results of phase one showed that the questionnaire did not provide sufficient 61 
information about the components of people’s beliefs and perceptions towards CFM. Therefore, a qualitative 62 
research was necessary to explain and build on the findings of phase one (Hadi and Closs 2016).  63 
 In order to ensure rigour, trustworthiness, transparency, and integrity of the findings, the methods 64 
required the following: 65 
• Triangulation: the results of phase two illuminated the different perspectives towards CFM problems 66 
identified in phase one (Long and Johnson 2000; Hadi and Closs 2016); 67 
• Clarification: the results of the quantitative method (phase one) using a qualitative method (FG) (Long 68 
and Johnson 2000; Hadi and Closs 2016); 69 
• Informed design: the FG method was based on the findings of the questionnaires, as these provided 70 
information from a large sample of the public about their experiences, views and beliefs of CFM (Long 71 
and Johnson 2000; Hadi and Closs 2016). 72 
• Peer debriefing, the researchers discussed the methodological process with knowledgeable peers on 73 
qualitative research on continuous basis (Long and Johnson 2000; Hadi and Closs 2016). 74 
• Participants’ validation, on completion of the study the findings were checked with participants 75 
(pharmacists only, since the public were difficult to trace back), meeting the diachronic reliability 76 
requirements of the findings, two years after the completion of the study (Long and Johnson 2000; Hadi 77 
and Closs 2016). 78 
The results of phase one were adopted using the explanatory sequential design process for developing the 79 
semi-structured guideline questions, for both the public (7 open-ended questions) (Table 1) and pharmacists 80 
(8 open-ended questions) (Table 2). Follow-up questions were asked to learn more, and probe about topics 81 
that participants brought up.  82 
 83 
Please insert Table 1 here 
 84 
Please insert Table 2 here 
 4 
Sample 85 
 86 
This study was conducted in Lebanon using two public FG with participants from different backgrounds, and 87 
two FG for pharmacists from different pharmacy settings. 88 
 89 
Public recruitment 90 
 91 
Two schools in ML were contacted for permission to use their sites. Schools were considered a convenience 92 
sampling method (Profetto-McGrath et al 2010) since it offered easy access to members of the public. The 93 
convenience sample of participants was chosen based on their visits to the principals’ offices. The principals 94 
were provided with the following exclusion criteria; any individual who; 1) was younger than 18 years old, 2) 95 
was not living in Lebanon, 3) did not approve of audiotaping the meeting, and 4) not willing to sign the consent 96 
form. The principals’ assistants asked each one if they would be interested in participating in the study. Those 97 
willing to participate were asked to register their names on a list with the assistant. Once the date was set, they 98 
were contacted and informed of the set times, and those able to attend were present. 99 
  100 
Pharmacists’ recruitment 101 
 102 
The recruitment of pharmacists used the snowball approach since the population was hard to reach, or 103 
recruit (Profetto-McGrath et al 2010) due to the sensitivity of the topic, and in order to avoid embarrassing or 104 
coercing pharmacists not willing to participate. The inclusion criterion was any pharmacist practicing in 105 
Lebanon (Lebanese Order of Pharmacists 1994). The exclusion criteria were pharmacists not living in 106 
Lebanon, who did not approve of using the audiotape during the meeting, and who was not willing to sign the 107 
consent form. Once the names were available, each pharmacist was contacted by telephone to explain the 108 
purpose behind the FG meetings. The call was followed by a confirmation email. 109 
 110 
Data collection  111 
 112 
The FG took place in the period between April to June 2014. Before starting each meeting, the moderator 113 
reviewed the consent form with participants and encouraged questions before signing the form. At the end of 114 
the meeting participants were given a demographic questionnaire to complete, and the moderator’s contact 115 
information for any additional questions. 116 
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 The primary author acted as the moderator for all FG, with the note-taker. Debriefing and observation 117 
discussions took place after each meeting between the moderator and note-taker. 118 
 119 
Data analysis 120 
 121 
The discussions of the public and pharmacists’ FG were transcribed, read and reviewed for each group. The 122 
analysis was performed by the inductive qualitative method followed by a structured process combining 123 
description and interpretation of the data (Kitzinger and Barbour 1999; Profetto-McGrath et al 2010) The 124 
reflexivity of the researchers was addressed by the objectivity of the results of phase one and the research 125 
question, independently of the researcher’s background, motives and perspectives. Each FG was analysed 126 
separately and then together (Kitzinger and Barbour 1999; Profetto-McGrath et al 2010) The analytical method 127 
used was thematic/category analysis as described by Kitzinger and Barbour (Kitzinger and Barbour 1999). 128 
With this method a theme is developed based on capturing something important in relation to the researched 129 
topic, irrespective of the number of persons who referred to it (Profetto-McGrath et al 2010). The public 130 
participants were considered aware of the meaning of CFM, if they said it was not the original, fake, or anything 131 
related. For pharmacists, the WHO definition was used as a reference (World Health Organization 2017). From 132 
the FG transcripts, meanings were interpreted, grouped and labelled with a code. The codes were compared 133 
and formed into themes and subthemes (Kitzinger and Barbour 1999; Long and Johnson 2000; Profetto-134 
McGrath et al 2010; Bellamy et al. 2016). The interpretation of data was based on the “intensity of comments”, 135 
“specificity of comments”, “internal consistency” and the “big ideas” in link with the research question (Rabiee 136 
2004). The validity of the interpretation is linked to the triangulation method mentioned above to minimize 137 
distortion (Long and Johnson 2000; Profetto-McGrath et al 2010) The relevant quotes were used to support a 138 
theme or an observation.   139 
 6 
Results  140 
 141 
Public FG 142 
 143 
The total number of public participants was 23. Their age ranged between 30 and 60, and 21 were female. 144 
Slightly more than one third of participants were between 31- 40 years old. The majority had a university 145 
degree, and lived in the ML region. Lack of awareness dominated the discussion, mixed with helplessness and 146 
mistrust in the system.  147 
 148 
Five main themes emerged from the two public FG discussions detailed in Table 3 with related quotes. 149 
 150 
Please insert Table 3 here 
 151 
Pharmacists FG 152 
 153 
The total number of participants was 13. Their age ranged between 26 and 60, 11 were females, and two thirds 154 
were between 26-30 years old. Participants were mostly from, and practicing in, ML and Beirut. Five worked 155 
with pharmaceutical companies, five in community, two in hospitals and one in both academia and community. 156 
They were motivated to discuss and share their concerns about CFM with other colleagues for the first time. 157 
Frustration and anger dominated the discussion. These emotions were associated with the perceived financial 158 
pressures and lack of professional ethics among pharmacists who deal with CFM. 159 
 160 
Five main themes emerged from the two pharmacist FG discussions detailed in Table 4 with related quotes.  161 
 162 
Please insert Table 4 here 
 163 
The duration of the discussions for the four FG was between 100-120 minutes. 164 
 165 
  166 
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Common themes between the public and pharmacists FG  167 
 168 
I. Awareness  169 
 170 
The discussions demonstrated a gap in participants’ awareness towards CFM: 1) Defining CFM; the majority 171 
of public participants were not able to define or provide a meaning to CFM, and either gave false definitions, 172 
or did not know. Pharmacist participants were able to define CFMs and were therefore considered aware of 173 
CFM. 2) Identifying CFM; a few of public participants were slightly knowledgeable and referred to the 174 
hologram, due to recent media reports. The majority of pharmacists expressed difficulty in identifying CFM, 175 
as they did not rely on the hologram, rather the relied on assessing patients’ responses to medicine. 3) CFM 176 
reporting System; No participants were aware of any reporting system, and were not sure how to report 177 
suspected CFM. 4) Prevalence and extent; according to pharmacist participants, CFM were mostly prevalent 178 
in the northern and southern parts of the country (away from the capital) and close to the borders where there 179 
is less control and implementation of regulations due to the current political situation. 180 
 181 
II. Trust 182 
 183 
The four FG participants expressed mistrust and lack of faith towards the system and some pharmacists. 1) 184 
The system; all participants believed that the Ministry of Public Health (MoPH) and the Lebanese Order of 185 
Pharmacists (OPL) were not carrying out their duties as should be, such as providing safe and effective 186 
medicine. Moreover, the public believed that pharmaceutical companies are involved in counterfeiting. 187 
According to pharmacist participants, the distribution channels and wholesalers were not well controlled and 188 
are not to be trusted. This appeared to originate from an incident in 2010 where CFM were available in some 189 
pharmacies through legal channels. Therefore, it would be crucial to control the supply chain. 2) Pharmacists; 190 
a few of the public participants believed that going to their trusted pharmacist would be one way to avoid 191 
buying CFM, the others distrusted pharmacists and believed they are all involved in the availability of CFM. 192 
The majority of pharmacist participants emphasized how the few pharmacists that were involved in CFM 193 
incidents affected their image, and how difficult it would be to regain the people’s respect and trust. 194 
 195 
III. Corruption 196 
 197 
All participants expressed their dissatisfaction, and believed the government and regulatory authorities were 198 
manipulating the affairs for private gains. Furthermore, participants stressed the weak implementation and 199 
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enforcement of the law that in their opinion led to diminished border and customs control. The systems’ actions 200 
were not for the public’s benefit, especially when no measures were taken against offenders. Pharmacists added 201 
that working in such conditions was becoming very difficult. 202 
 203 
IV. Overcoming counterfeit medicine 204 
 205 
Participants suggested that responsible authorities should use different methods to discourage and stop 206 
counterfeiters and the use by the public of CFM. Five subthemes emerged: 1) Education; the discussions and 207 
exchange of experiences among public participants demonstrated the need to learn and understand more about 208 
CFM and the need for authorities to be more transparent. All pharmacists believed in their need to be educated 209 
and to educate patients about CFM. Pharmacists emphasized the importance of knowledge, stressing the “know 210 
how” that is always missing. The majority of pharmacists raised the concern that physicians should also be 211 
aware and educated regarding CFM, as there seemed to be a lack of awareness among physicians. 2) Laws 212 
and regulations; all participants agreed on the need for laws and regulations to be implemented and enforced. 213 
In addition, there is a need to develop a CFM reporting system and a point of reference where the MoPH and 214 
OPL can be available and involved. 3) Responsibility and accountability; the public participants believed 215 
that naturally the MoPH should be responsible for guaranteeing that safe and effective medicine to reach 216 
pharmacies. They suggested using different methods to discourage and stop counterfeiters. 4) Central 217 
laboratory; all pharmacists highlighted the need for the MoPH to reactivate the national laboratory, to 218 
randomly test samples of medicine in the country. 5) Dedicated pharmacists; the majority of pharmacists 219 
believed they could have a major role in controlling the availability of CFM, through organizing and 220 
controlling the pharmacy profession, to stop the outliers. 221 
 222 
Uncommon themes 223 
 224 
V. Locus of control 225 
 226 
This theme reflected the degree that participants’ perceived events to be under their control (internal) or under 227 
the control of others who are more powerful (external) as the following subthemes: 1) Internal control; 228 
participants’ believed that controlling the events and outcomes themselves were dependent on their knowledge. 229 
The majority highlighted that people in general lacked enough knowledge about medicine, and thus did not 230 
know what to do. 2) External control; participants’ believed they did not have the power to control events or 231 
outcomes, rather relying on outside influences or external factors such as other people, government, or fate.  232 
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These external factors were subdivided into: a) Worries; participants’ worries and concerns relating to the 233 
outcome of their medicine if counterfeit. b) Financial concern; the high cost of medicine was the reason 234 
behind the availability of CFM. Patients would unknowingly go for a cheaper medicine if given a choice. c) 235 
Political instability; the majority of participants seemed overwhelmed with the country’s political instability, 236 
and did not consider CFM a priority for the government or politicians. Participants considered themselves 237 
unworthy of “good” medicine. 238 
 239 
VI. Reasons for availability of CFM 240 
 241 
The following subthemes emerged while pharmacists’ FGs were describing the reasons for CFM availability: 242 
1) Pharmacists; for the following reasons: a) Business and profit; the majority believed that there are some 243 
unethical pharmacists who do not care, and each community has pharmacists that deal with CFM, thus 244 
contributing to the mistrust of pharmacists. Moreover, some pharmacists illegally discounted the medicine 245 
priced by the MoPH to appear more compassionate towards patients, when the discounted medicine may be 246 
counterfeit. b) Professional experience; participants shared their experiences about being approached and 247 
offered CFM. Participants reported how dealers always checked around and offered CFM to those interested, 248 
and would target new pharmacies, young graduates or the inexperienced for their tendency to be more 249 
vulnerable than others. Older participants stated they were also approached when they opened their pharmacies, 250 
and due to their continuous rejections, were no longer approached. 2) Medicine shortages; the majority 251 
believed that counterfeiters took advantage of medicine shortages and offered cheaper alternatives or provided 252 
attractive offers for medicine that could only be counterfeit. 3) Demand; the majority reported in believing 253 
that patients end up buying CFM due to the high cost of medicine, and the financial situation caused by the 254 
political instability. Participants believed that some members of the public may be aware but do not care and 255 
choose the cheaper medicine (CFM), and some lack awareness. 4) Control; participants reported that their 256 
concerns were due to the MoPH’s lack of control of available medicine and the supply chain. Pharmacists 257 
expressed that they had limited control and were under a lot of pressure. 258 
 259 
The structure of the thematic network for the four FG is presented in Fig1. 260 
 261 
Please insert Fig 1 here 
  262 
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Discussion  263 
 264 
The study explored the views, experiences, and beliefs of the public and pharmacists towards CFM using FG. 265 
The study applied the mixed methods methodology using both quantitative and qualitative research. Four 266 
common themes emerged among all participants indicating the similar views and beliefs about CFM, reflecting 267 
their own perceptions and experiences. The discussions showed a lack of experience and limited awareness 268 
regarding CFM among the public, however pharmacists were aware but the level of expertise appeared related 269 
to the number of years in practice. The study sample for all groups had an over-representation of females, thus 270 
the results might be gender specific, as studies show that males and females do have different views and beliefs 271 
(Abbey 1982). 272 
 273 
Contributing factors to CFM 274 
 275 
No participants were aware of the CFM reporting system, and considered the pharmacy a reasonable place for 276 
reporting suspected CFM. One study also expressed pharmacists’ need for an official CFM reporting system, 277 
and also counselling patients about the system and CFM (Jackson et al. 2012; Sholy et al. 2017). Moreover, 278 
pharmacists indicated that CFM were more prevalent in the North, South, and Bekaa in accordance with phase 279 
one of the study (Sholy 2015) where the extent of CFM ranged from 3% in ML to 12.1% in the South and the 280 
Bekaa. The difficulty expressed by participants in identifying CFM was supported by other studies on how 281 
easy it is becoming to counterfeit (Kitzinger and Barbour 1999; Deisingh 2005; Newton et al. 2006; Sholy 282 
2015). 283 
 The mistrust towards the MoPH, OPL, pharmacists, regulatory authorities and pharmaceutical companies 284 
was probably due to what participants considered lack of transparency and professional misconduct. The 285 
findings were in accordance with the WHO which states that counterfeiting is contributing to the damaging of 286 
the reputation of pharmaceutical companies by destroying public confidence and trust in medicine, which 287 
causes the reluctance of some companies to publicize incidents of their products being counterfeited (Kahn et 288 
al. 2012). 289 
 The continuous increase in the number of graduating pharmacists’ year on year was reported to have 290 
decreased pharmacists’ minimum wages to $1350/month (Lebanese Order of Pharmacists 2014) which might 291 
have contributed to some pharmacists being involved in the reported incidents involving CFM (Sholy et al. 292 
2017). Many studies have documented the impact pharmacists can play in improving patients’ health outcome, 293 
and decreasing the chances of dispensing CFM (Chauvé 2008; Law and Youmans 2011; Jackson et al. 2012; 294 
Alfadl et al. 2013; Rajapandian et al. 2013; Mdege et al. 2016). However, the good or bad headlines do 295 
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influence the perception of the pharmacy profession, therefore, more efforts are required to enhance the 296 
reputation of the profession, and improve pharmacists’ image to regain the trust of the public (DiPiro 2011). 297 
 Trust is an important asset the public can give to healthcare professionals when their work is for furthering 298 
social justice and public health (Kass 2001). According to the UK code of ethics, the public need to trust that 299 
they are pharmacists’ primary concern, and that pharmacists are honest, trustworthy, and protective of patients 300 
from any harm by providing safe and effective medicine (General Pharmaceutical Council 2017). To date, 301 
there is no known or published code of ethics for pharmacists in Lebanon; consequently, the OPL should 302 
consider agreeing on a code that all registered pharmacists must follow (Sholy et al. 2017). 303 
 The mistrust theme is related to corruption according to a study that measured the degree of trust in 304 
societies around the world, which varied considerably and was strongly correlated with views about crime and 305 
corruption (Wike and Holzwart 2008). The study also reported that 67% of the Lebanese respondents disagreed 306 
that most people in society are trustworthy, compared to Egypt (40%), Jordan (45%) and Kuwait (71%). 307 
Moreover, the Lebanese and Nigerian’s trust was rare due to respondents’ reported concern about widespread 308 
of political corruption. In fact, in countries where people reported trusting each other, there were less worries 309 
about crime or corrupt political leaders (Wike and Holzwart 2008). This study’s participants stated the need 310 
for clear laws to be implemented and enforced, although they did not believe that their suggestions would be 311 
implemented or would change anything, since corruption is so deeply rooted in the culture. Cultures of 312 
corruptions will not fade away (Tanzi 1998) and according to participants, this is the case in Lebanon. 313 
 Consequently, the belief that corruption had a role in the availability of CFM is also reported in the USA 314 
and UK, where corruption among wholesalers and illegal supply chains allowed CFM to enter their legal chain 315 
system (Besançon 2008; Mackey et al. 2015). The problem of medicine shortage in Lebanon is also a global 316 
concern that counterfeiters take advantage of (Newton et al. 2006) as they use original holograms on 317 
counterfeits (Sholy 2015). This would explain why pharmacists reported not relying on holograms. 318 
Furthermore, participants stated that shortage of medicine increases the demand for cheaper medicine which 319 
are highly likely to be counterfeits, which is supported by a number of studies (Chauvé 2008; Alfadl et al. 320 
2013; Rajapandian et al. 2013; Mdege et al. 2016). In Poland, people who had low monthly income found the 321 
low cost of CFM attractive, and consciously bought them due to their availability and low cost, increasing the 322 
demand for CFM (Binkowska‐Bury et al. 2013). 323 
 324 
Overcoming factors to CFM 325 
 326 
Participants also emphasised the need for the government to develop legal frameworks and strong legislations 327 
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regulating medicine, with severe penalties to deter counterfeiters, as supported by several other studies 328 
(Syhakhang et al 2004; Chauvé 2008; Alfadl et al. 2013; Al-Worafi 2014; Mdege et al. 2016). Their 329 
suggestions were in support of the OPL with pharmacists being positioned at customs and within hospitals. 330 
There were also further suggestions to reactivate the national laboratory to test and control supply chain of all 331 
medicines in the Lebanese market, to ensure safety (Chauvé 2008; Lebanon Pharmaceuticals and Healthcare 332 
2010; Rajapandian et al. 2013; Sholy et al. 2017).  333 
 All participants indicated that education was key, and considered education the turning point for 334 
controlling CFM availability as supported by other studies (Alfadl et al. 2013; El Jardali et al. 2015; Sholy et 335 
al. 2017). Participants demonstrated the need to establish a centralized and standardized reporting system, such 336 
as Medwatch that encourages voluntary reporting of suspected CFM (U.S. Food and Drug Administration 337 
2016). The burden of CFM can then be estimated by costs of hospitalizations or ambulatory settings for treating 338 
the consequences of CFM use (Akiny 2013). 339 
Identifying the appropriate interventions required for the educational, managerial and regulatory programs 340 
may lead to the development of beneficial interventions. Additionally, pharmacists’ awareness and CFM 341 
education can play a key role in educating and counselling patients about CFM that can empower the public 342 
by decreasing their vulnerability towards CFM, improving detection and reporting of CFM, thus reducing their 343 
availability/use. 344 
 345 
Limitations 346 
 347 
When approached, not all pharmacists were enthusiastic or willing to participate in the study. The FG were 348 
conducted in ML, the region with the lowest incidences of CFM use. There was a bias in the sample of the 349 
public participants, as the majority had university degrees, were females and were in the same age group.   350 
 13 
Conclusion 351 
This is the first FG study to generate insight on awareness among the public, and pharmacists regarding CFM 352 
in Lebanon. The results were consistent with previous studies on the need for changes related to regulations, 353 
enforcement of the law, and updating pharmacists’ CFM knowledge. Additionally, emphasised the role of high 354 
prices and the unaffordability of medicines in increasing vulnerability of the public to using CFM. Finally, 355 
there is a need for future mixed methods research to assess and confirm the themes suggested in this study.  356 
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